Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Inhibition of ApoCIII: the next PCSK9?
Bernelot Moens SJ, van Capelleveen JC, Stroes ES. Bernelot Moens SJ, et al. Among authors: van capelleveen jc. Curr Opin Lipidol. 2014 Dec;25(6):418-22. doi: 10.1097/MOL.0000000000000130. Curr Opin Lipidol. 2014. PMID: 25255477 Review.
Relationship of lipoprotein-associated apolipoprotein C-III with lipid variables and coronary artery disease risk: The EPIC-Norfolk prospective population study.
van Capelleveen JC, Lee SR, Verbeek R, Kastelein JJP, Wareham NJ, Stroes ESG, Hovingh GK, Khaw KT, Boekholdt SM, Witztum JL, Tsimikas S. van Capelleveen JC, et al. J Clin Lipidol. 2018 Nov-Dec;12(6):1493-1501.e11. doi: 10.1016/j.jacl.2018.08.010. Epub 2018 Aug 29. J Clin Lipidol. 2018. PMID: 30249512 Free PMC article.
Current therapies for lowering lipoprotein (a).
van Capelleveen JC, van der Valk FM, Stroes ES. van Capelleveen JC, et al. Among authors: van der valk fm. J Lipid Res. 2016 Sep;57(9):1612-8. doi: 10.1194/jlr.R053066. Epub 2015 Dec 4. J Lipid Res. 2016. PMID: 26637277 Free PMC article. Review.
Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.
Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ, Marcovina SM, Hughes SG, Graham MJ, Crooke RM, Crooke ST, Witztum JL, Stroes ES, Tsimikas S. Viney NJ, et al. Among authors: van capelleveen jc. Lancet. 2016 Nov 5;388(10057):2239-2253. doi: 10.1016/S0140-6736(16)31009-1. Epub 2016 Sep 21. Lancet. 2016. PMID: 27665230 Clinical Trial.
Apolipoprotein C-III Levels and Incident Coronary Artery Disease Risk: The EPIC-Norfolk Prospective Population Study.
van Capelleveen JC, Bernelot Moens SJ, Yang X, Kastelein JJP, Wareham NJ, Zwinderman AH, Stroes ESG, Witztum JL, Hovingh GK, Khaw KT, Boekholdt SM, Tsimikas S. van Capelleveen JC, et al. Arterioscler Thromb Vasc Biol. 2017 Jun;37(6):1206-1212. doi: 10.1161/ATVBAHA.117.309007. Epub 2017 May 4. Arterioscler Thromb Vasc Biol. 2017. PMID: 28473441 Free PMC article.
Arterial and Cellular Inflammation in Patients with CKD.
Bernelot Moens SJ, Verweij SL, van der Valk FM, van Capelleveen JC, Kroon J, Versloot M, Verberne HJ, Marquering HA, Duivenvoorden R, Vogt L, Stroes ES. Bernelot Moens SJ, et al. Among authors: van capelleveen jc. J Am Soc Nephrol. 2017 Apr;28(4):1278-1285. doi: 10.1681/ASN.2016030317. Epub 2016 Oct 31. J Am Soc Nephrol. 2017. PMID: 27799487 Free PMC article.
Genetics of HDL-C: a causal link to atherosclerosis?
van Capelleveen JC, Bochem AE, Motazacker MM, Hovingh GK, Kastelein JJ. van Capelleveen JC, et al. Curr Atheroscler Rep. 2013 Jun;15(6):326. doi: 10.1007/s11883-013-0326-8. Curr Atheroscler Rep. 2013. PMID: 23591671 Review.
Genetic variants in SUSD2 are associated with the risk of ischemic heart disease.
Bruikman CS, Dalila N, van Capelleveen JC, Kroon J, Peter J, Havik SR, Willems M, Huisman LC, de Boer OJ, Hovingh GK, Tybjaerg-Hansen A, Dallinga-Thie GM. Bruikman CS, et al. Among authors: van capelleveen jc. J Clin Lipidol. 2020 Jul-Aug;14(4):470-481. doi: 10.1016/j.jacl.2020.05.100. Epub 2020 Jun 3. J Clin Lipidol. 2020. PMID: 32620384
22 results